Natera

Director of Marketing, Oncology Market Analytics and Competitive Intelligence

United States

Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Healthcare, Biotechnology, PharmaceuticalsIndustries

Requirements

Candidates should possess a Bachelor’s degree in life sciences, with an advanced degree (MBA, PhD) preferred, and a minimum of 2 years of experience in strategic or management consulting. They must also have 7–10 years of experience in product marketing, field sales, or market analytics within the pharmaceutical, biotech, or life sciences industry, with strong preference for oncology experience. The role requires the ability to travel up to 25% for advisory boards, industry congresses, sales/marketing meetings, and customer engagements.

Responsibilities

The Director of Marketing will co-develop tumor-specific market opportunity assessments and gap analyses, synthesize insights from various sources, and own the strategic framing of tumor-level and pan-oncology market opportunities. They will support the development of cross-portfolio positioning strategies, design and lead primary market research, quantify the total addressable market, collaborate with field analytics and marketing partners to identify growth opportunities, develop KPIs and dashboards, and contribute to cross-functional planning initiatives. The role also involves performing other duties as assigned.

Skills

Market research
Data analysis
Strategic planning
Market opportunity assessment
Customer insights
Segmentation
ROI analysis
Dashboard development
Cross-functional collaboration

Natera

Genetic testing and diagnostics solutions provider

About Natera

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care and health outcomes through accurate genetic testing.

Austin, TexasHeadquarters
2004Year Founded
$149.9MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
1,001-5,000Employees

Benefits

Flexible medical plans
Investment options
Time off
Workplace perks

Risks

Hindenburg report accuses Natera of deceptive sales practices, risking legal challenges.
New Prospera Heart features may face slow adoption by healthcare providers.
Fetal RhD NIPT demand may drop post-RhIg shortage, affecting future sales.

Differentiation

Natera's Signatera test offers personalized ctDNA analysis for cancer patients.
Prospera Heart test uses unique Donor Quantity Score for transplant rejection detection.
Panorama NIPT test is a leader in non-invasive prenatal testing with 2 million tests.

Upsides

Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.
AI integration enhances accuracy and speed of Natera's cfDNA analysis.
Growing personalized medicine trend aligns with Natera's customized genetic tests.

Land your dream remote job 3x faster with AI